Graviton

Graviton develops novel therapeutics for the treatment of autoimmune, cancer, certain genetic, fibrotic, and other serious diseases. TDI01, a highly selective, potent inhibitor of Rho/Rho-associated coiled-coil containing protein kinase 2 (ROCK2) is currently being studied in the United States for the treatment of idiopathic pulmonary fibrosis (IPF). Graviton anticipates entering human clinical studies in the U.S. in 2021.

Domain

graviton.bio

Employees

11-50

Last Funding

$39.8M

Founded

2019

Frequently Asked Questions

What technologies does Graviton use?+

Graviton uses 10 technologies including SeedProd Coming Soon, WordPress, jQuery.

What industry is Graviton in?+

Graviton operates in the Biotechnology industry.

Where is Graviton based?+

Graviton is headquartered in United States.

Need this data at scale?

Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.

Browse Datasets

Data last updated: June 2026